Vandria Secures $30.7M to Advance Mitochondrial Therapeutics

Vandria, a pioneer in mitochondrial therapeutics, has successfully raised $30.7 million in its Series A financing round. This funding will fuel the company's groundbreaking work on small molecule mitophagy inducers aimed at rejuvenating cells and tackling age-related and chronic diseases.

• Series A Funding Milestone: Vandria's latest financing round includes contributions from the Hevolution Foundation, Dolby Family Ventures, and lead investor ND Capital.

• Innovative Therapeutics: Vandria focuses on small molecule mitophagy inducers targeting novel pathways. Their goal is to induce mitophagy—removing damaged mitochondria—and provide anti-inflammatory effects to combat various diseases.

• Pipeline Overview: The company is advancing VNA-318, designed to enhance cognition and slow memory loss in early-stage CNS and neurodegenerative disorders. Additional compounds aim to address muscle, lung, and liver diseases.

Vandria is set to continue its journey toward clinical trials, leveraging its new investments and resources to bring innovative treatments to market.